Cardiovascular Disease 2050: No, GLP-1s Won't Save the Day

Cardiologists Bob Harrington and Dhruv Kazi discuss the projected burden of cardiovascular disease in 2050, why it's not sustainable, and what can be done to prevent it.

This podcast is intended for healthcare professionals only.

To read a transcript or to comment, visit https://www.medscape.com/author/bob-harrington

INCLUDE URLS and full titles for some of the pertinent studies cited.

Forecasting the Burden of Cardiovascular Disease and Stroke in the United States Through 2050

https://doi.org/10.1161/CIR.0000000000001256

Forecasting the Economic Burden of Cardiovascular Disease and Stroke in the United States Through 2050

https://doi.org/10.1161/CIR.0000000000001258

Calculating the 30-day Survival Rate in Acute Myocardial Infarction: Should we Use the Treatment Chain or the Hospital Catchment Model?

https://doi.org/10.5301/heartint.5000238

Life's Essential 8: Updating and Enhancing the American Heart Association's Construct of Cardiovascular Health

https://doi.org/10.1161/CIR.0000000000001078

Current Trends in Hypertension Identification and Management: Insights from the National Health and Nutrition Examination Survey

https://doi.org/10.1161/JAHA.123.034322

Youth-Onset Type 2 Diabetes: The Epidemiology of an Awakening Epidemic

https://doi.org/10.2337/dci22-0046

US Trends in Cholesterol Screening, Lipid Levels, and Lipid‐Lowering Medication Use in US Adults, 1999 to 2018

https://doi.org/10.1161/JAHA.122.028205

GLP-1 Receptor Agonist Discontinuation Among Patients With Obesity and/or Type 2 Diabetes

https://pubmed.ncbi.nlm.nih.gov/38787563

Health Care by Food

https://healthcarexfood.org/

You may also like:

Hear John Mandrola, MD's summary and perspective on the top cardiology news each week, on This Week in Cardiology

https://www.medscape.com/twic

Questions or feedback, please contact

news@medscape.net